Clinical Trial Update: JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a JAK inhibitor for acquired hemophagocytic syndrome in ICU patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Syndromes

Drugs mentioned

• JAK inhibitor

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hemophagocytic Syndromes | Phase 2 | Status: UNKNOWN